To validate the relevance of our findings to human CRC and to further examine whether hindering CHD6-TMEM65 signaling axis can control the capacity of tumor formation in human CRC, we established PDXs40 by implanting primary tumor samples resected from CRC patients into the immunocompromised mice. The gene discussed is CHD6; the disease is colorectal carcinoma.